--- title: "CorMedix (CRMD) news: class action and offering" url: "https://aibio.space/companies/cormedix/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CRMD class action, offering, convertible notes and settlement news: CorMedix faces DefenCath securities class action as derivative settlement heads to a…" --- CRMD CorMedix Inc. NASDAQ · United States # CorMedix (CRMD) news CRMD class action, offering and convertible notes news Legal · 2026-08-13 ## [CorMedix faces DefenCath securities class action as derivative settlement heads to a hearing](https://aibio.space/news/cormedix-faces-defencath-securities-class-action-derivative-settlement/) The class action names CorMedix and six officers, including Khoso Baluch. A settlement of derivative suits naming 12 individuals had a final approval hearing set for September 23, 2026. ## Latest CorMedix news 1. 2026-04-29 Listings [CorMedix asks holders to ratify past changes to preferred stock terms](https://aibio.space/news/cormedix-asks-holders-ratify-past-changes-preferred-stock-terms/) CorMedix wants stockholders to ratify earlier changes to its Series E and Series C-3 preferred stock, and to let preferred holders alone approve future changes to those terms. 2. 2025-09-02 Mergers [CorMedix completes Melinta Therapeutics acquisition for $300 million in upfront consideration](https://aibio.space/news/cormedix-completes-melinta-therapeutics-acquisition-300-million/) CorMedix paid $260 million in cash and $40 million in common shares to Melinta's owners. A contingent payment agreement adds up to $25 million tied to a rezafungin approval by June 30, 2029. 3. 2025-08-12 Debt Financing [CorMedix completes $150,000,000 convertible senior notes private placement due 2030](https://aibio.space/news/cormedix-completes-150-000-000-convertible-senior-notes-offering-due/) CorMedix closed a $150,000,000 private placement of 4.00% convertible senior notes due 2030 on August 12, 2025. Each $1,000 of principal converts into 74.2515 common shares at the initial rate, and U.S. Bank Trust Company is trustee under the new indenture. 4. 2025-08-12 Debt Financing [CorMedix completes $150,000,000 convertible senior notes offering due 2030](https://aibio.space/news/cormedix-completes-150-000-000-convertible-senior-notes-offering-due/) The 4.00% notes were sold in a private placement. The initial conversion rate is 74.2515 shares of common stock per $1,000 principal amount. 5. 2025-08-07 Mergers [CorMedix to buy Melinta Therapeutics, closing targeted as early as September 1](https://aibio.space/news/cormedix-buy-melinta-therapeutics-closing-targeted-early-september-1/) CorMedix said it will buy Melinta Therapeutics, with closing targeted as early as September 1, 2025. The company's August 7 release gives no price, no financing and no adviser for the deal. ## CorMedix at a glance - **Ticker**: CRMD - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $256.7 million ### Related companies - [Fennec Pharmaceuticals](https://aibio.space/companies/fennec-pharmaceuticals/) NASDAQ: FENC - [BANGI INC](https://aibio.space/companies/bangi/) OTC: BNGI - [Vaxcyte](https://aibio.space/companies/vaxcyte/) NASDAQ: PCVX - [Surrozen](https://aibio.space/companies/surrozen/) NASDAQ: SRZN - [Evofem Biosciences](https://aibio.space/companies/evofem-biosciences/) OTC: EVFM - [Equillium](https://aibio.space/companies/equillium/) NASDAQ: EQ - [C4 Therapeutics](https://aibio.space/companies/c4-therapeutics/) NASDAQ: CCCC - [Rapport Therapeutics](https://aibio.space/companies/rapport-therapeutics/) NASDAQ: RAPP ### Also on NASDAQ - [Silence Therapeutics](https://aibio.space/companies/silence-therapeutics/) SLN - [Crescent Biopharma](https://aibio.space/companies/crescent-biopharma/) CBIO - [Adial Pharmaceuticals](https://aibio.space/companies/adial-pharmaceuticals/) ADIL - [908 Devices](https://aibio.space/companies/908-devices/) MASS - [Prenetics Global](https://aibio.space/companies/prenetics-global/) PRE - [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) VERA ## What CorMedix does CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Its main commercial product is DefenCath (taurolidine and heparin), an antimicrobial catheter lock solution that the FDA approved to reduce catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter. The company launched DefenCath in April 2024 in the inpatient setting and in July 2024 in the outpatient hemodialysis setting, and says it is its largest contributor to net sales. On August 29, 2025 it acquired Melinta Therapeutics, adding six marketed, hospital- and clinic-focused infectious disease products: REZZAYO, MINOCIN IV, VABOMERE, KIMYRSA, ORBACTIV and BAXDELA. The acquisition also added TOPROL-XL. The company plans to pursue expanded indications for DefenCath to reduce central line associated bloodstream infection in adults receiving total parental nutrition, and for REZZAYO in prophylaxis of invasive fungal infections in immunocompromised adults. | Product or program | What it is | Stage | |---|---|---| | DefenCath | Antimicrobial catheter lock solution for hemodialysis patients | approved | | REZZAYO | Rezafungin for injection, a hospital infectious disease product | marketed | | MINOCIN IV | Minocycline for injection, a hospital infectious disease product | marketed | | VABOMERE | Meropenem and vaborbactam, a hospital infectious disease product | marketed | Summarised from the company's [10-K filed Mar 5, 2026](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/ea0278169-10k_cormedix.htm). ## CorMedix annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$311.7 million](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/) | [$43.5 million](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/) | | Research and development | [$19.3 million](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/) | [$3.9 million](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/) | | Net income (loss) | [$163.1 million](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/) | [-$17.9 million](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/) | | Cash from operations | [$175.0 million](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/) | [-$50.6 million](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/) | | Cash and equivalents | [$144.8 million](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000056/) | [$40.7 million](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/) | | Short-term investments | [$3.7 million](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000056/) | [$11.0 million](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $256.7 million, plus short-term investments of $0, $256.7 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about CorMedix Is there a class action against CorMedix? Our latest story on this, dated Aug 13, 2026: "CorMedix faces DefenCath securities class action as derivative settlement heads to a hearing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cormedix-faces-defencath-securities-class-action-derivative-settlement/). Has CorMedix raised money recently? Our latest story on this, dated Aug 12, 2025: "CorMedix completes $150,000,000 convertible senior notes private placement due 2030". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cormedix-completes-150-000-000-convertible-senior-notes-offering-due/). Has CorMedix sold convertible notes? Our latest story on this, dated Aug 12, 2025: "CorMedix completes $150,000,000 convertible senior notes private placement due 2030". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cormedix-completes-150-000-000-convertible-senior-notes-offering-due/). Has CorMedix settled a lawsuit? Our latest story on this, dated Aug 13, 2026: "CorMedix faces DefenCath securities class action as derivative settlement heads to a hearing". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cormedix-faces-defencath-securities-class-action-derivative-settlement/). What is the ticker symbol of CorMedix? CorMedix Inc. trades under the ticker CRMD on NASDAQ. Where is CorMedix listed? CorMedix Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:19KA; LSX:A2PF3G. What is the SEC CIK of CorMedix? The SEC Central Index Key (CIK) for CorMedix Inc. is 1410098. Its filings are on SEC EDGAR. How many shares does CorMedix have outstanding? 77,944,324 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is CorMedix listed under? Our directory records CorMedix Inc. under United States. What does CorMedix do? Our directory classifies CorMedix Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of CorMedix? The ISIN recorded for CorMedix Inc. is US21900C3088. Does aibio.space cover CorMedix? aibio.space lists CorMedix Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is CorMedix incorporated? SEC records list its state or country of incorporation as DE. What does CorMedix develop? CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. Its main commercial product is DefenCath (taurolidine and heparin), an antimicrobial catheter lock solution that the FDA approved to reduce catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter. What is DefenCath from CorMedix? DefenCath: Antimicrobial catheter lock solution for hemodialysis patients Stage: approved. ## Investor discussion: CorMedix Members talk about CorMedix (CRMD). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at CorMedix, newest first. Each line links the filing it comes from. 1. 2026-08-07 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000044/crmd-8xkxaugust72026xex991.htm) 2. 2026-07-01 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01). [Source](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000037/crmd-20260625.htm) 3. 2026-04-29 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1410098/000121390026049311/ea0286136-05.htm) 4. 2026-04-17 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1410098/000121390026045165/ea0286136-02.htm) 5. 2025-08-12 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1410098/000121390025075010/ea0252859-8k_cormedix.htm) 6. 2025-08-07 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,2.02,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1410098/000121390025072814/ea025204301ex99-1_cormedix.htm) 7. 2025-06-26 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1410098/000121390025058406/ea0246889-424b5_cormedixinc.htm) 8. 2025-04-22 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1410098/000121390025034219/ea0238857-8k_cormedix.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CRMD on TradingView](https://www.tradingview.com/symbols/NASDAQ-CRMD/). ## SEC filings and registration - **SEC name**: CorMedix Inc. - **CIK**: 1410098 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CRMD (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: 389 INTERPACE PKWY, SUITE 450, PARSIPPANY, NJ, 07054 - **Phone**: 908-517-9500 - **Shares outstanding**: 77,944,324 as of 2026-08-10 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1410098/000121390026110477/ea0308957-8k_cormedix.htm) filed 2026-10-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000056/crmd-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000054/crmd-20260813.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000044/crmd-20260807.htm) filed 2026-08-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000040/crmd-20260629.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000037/crmd-20260625.htm) filed 2026-07-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1410098/000141009826000028/crmd-20260623.htm) filed 2026-06-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1410098/000121390026066061/ea0293895-8k_cormedix.htm) filed 2026-06-08 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001410098), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details CorMedix Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CRMD, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: CorMedix Inc. - **Ticker**: CRMD - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US21900C3088 - **Other listed symbols**: GETTEX:19KA; LSX:A2PF3G - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CRMD/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cormedix/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CorMedix (CRMD) news: class action and offering", 2026-10-31, https://aibio.space/companies/cormedix/